Buy Ipigrix ampoules 15mg/ml 1.0 ml ampoule 10pcs
  • Buy Ipigrix ampoules 15mg/ml 1.0 ml ampoule 10pcs


1681 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Pharmacotherapeutic group: Anticholinesterase agents.


Pharmacological properties


Ipidacrine is a reversible inhibitor of cholinesterase. It directly stimulates the conduction of impulses in the central nervous system (CNS) and neuromuscular synapses, blocking the potassium channels of the membranes. Enhances the effect on smooth muscles not only of the mediator acetylcholine, but also of adrenaline, serotonin, histamine and oxytocin.

Main pharmacological effects of ipidacrine:

- restoration and stimulation of neuromuscular conduction;

- restoration of impulse conduction in the peripheral nervous system after blockade caused by certain factors (for example, trauma, inflammation, local anesthetics, antibiotics, toxins and potassium chloride);

- increased contractility and tone of the smooth muscles of the internal organs;

- specific moderate stimulation of the CNS in combination with individual manifestations of sedative action;

- memory improvement.

In preclinical studies, ipidacrine had no teratogenic, embryotoxic, mutagenic, carcinogenic, or immunotoxic effects, and did not affect the endocrine system.

Sufficient data from clinical studies of the safety of ipidacrine in children are not available.



After oral administration, ipidacrine is rapidly absorbed from the gastrointestinal tract. The maximum concentration in plasma after subcutaneous or intramuscular administration is achieved within 25-30 minutes. About 40-55% of the active substance is bound to plasma proteins. The therapeutic effect appears 15–20 minutes after parenteral administration. The duration of the drug is 3-5 hours.


The drug penetrates the blood-brain barrier. Ipidacrine rapidly enters the tissue, only 2% of the drug is found in the plasma in an equilibrium state.

Metabolism and excretion

The drug is metabolized in the liver. Ipidacrine excretion is renal and extrarenal (through the gastrointestinal tract), excretion with urine prevails. The half-life of ipidacrine is 40 min. After parenteral administration, 34.8% of the applied dose of ipidacrine is excreted unchanged in the urine. This indicates a rapid metabolism of the drug in the body.


- Diseases of the central nervous system: bulbar paralysis and paresis.

- Diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies).

- The period of recovery after organic lesions of the central nervous system, accompanied by motor impairment.


1 ml of solution contains:

active ingredient: ipidacrine hydrochloride monohydrate - 5.4 mg or 16.2 mg (in terms of ipidacrine hydrochloride - 5.0 mg or 15.0 mg);

excipients: 1 M solution of hydrochloric acid to pH 2.8-4.0, water for injection to 1 ml.


Transparent colorless liquid.

Ipidacrine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Ipigrix Grindex Latvia ampoules
Ipigrix Grindex Latvia pills
Axamon Ellara Russia solution
Axamon Ellara Russia pills
Neuromidin Olainfarm Latvia ampoules
Neuromidin Olainfarm Latvia pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Intramuscular or subcutaneous.

Doses and duration of treatment are determined individually depending on the severity of the disease.

Peripheral nervous system diseases

  • Mono- and polyneuropathy of various genesis: subcutaneously and intramuscularly 5-15 mg 1-2 times a day, a course of 10-15 days (in severe cases, up to 30 days); then move to taking ipidacrine pills.

  • Myasthenia gravis and myasthenic syndrome: subcutaneously and intramuscularly 5–30 mg 1–3 times a day; then move to taking ipidacrine pills. The general course of treatment is 1–2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months.

Diseases of the central nervous system

  • Bulbar paralysis and paresis: subcutaneously and intramuscularly 5-15 mg 1-2 times a day, a course of 10-15 days; then move to taking ipidacrine pills.

  • Rehabilitation for organic lesions of the central nervous system: intramuscularly 10-15 mg 1–2 times a day, a course of up to 15 days; then move to taking ipidacrine pills.

Adverse reactions

Ipidacrine is usually well tolerated. Side effects are mainly associated with the stimulation of m-cholinergic receptors.

The following side effects of ipidacrine are classified into groups of systems and organs, indicating the frequency of occurrence: often (≥1 / 100 to infrequently (≥1 / 1000 to rarely (≥1 / 10 000 to

Disorders of the gastrointestinal tract

Often: hypersalivation, nausea.

Infrequently: vomiting.

Rarely: diarrhea, epigastric pain.

Unknown: dyspepsia.

Nervous system disorders

Infrequently: dizziness, headaches, drowsiness, muscular spasm, weakness.

Impaired cardiac function

Often: palpitations, bradycardia.

Violations of the organs of sight

Unknown: miosis.

Disorders of the respiratory system, chest and mediastinum

Infrequently: increase in bronchial secretion, bronchospasm.

Disorders of the musculoskeletal system and connective tissue

Unknown: tremor, convulsions, increasing the tone of the uterus.

Violations of the skin and subcutaneous tissue

Often: sweating.

Infrequently: allergic reactions (itching, rash), usually when using large doses of the drug.

General disorders and reactions at the site of administration

Unknown: hypothermia, chest pain, jaundice.

If these side effects appear, or if a side effect occurs that is not mentioned in the instructions, you should consult a doctor.

Drug interactions

Ipidacrine reduces the inhibitory effect on the neuromuscular transmission and conduction of excitation along the peripheral nerves of local anesthetics, aminoglycosides and potassium chloride.

The sedative effect of drugs that inhibit the central nervous system, including ethanol, as well as the effect of other cholinesterase inhibitors and m-cholinomimetic substances under the influence of ipidacrine is enhanced.

With the simultaneous use of other cholinergic drugs ipidacrine increases the risk of a cholinergic crisis in patients with myasthenia.

Beta-adrenolytic agents increase the severity of bradycardia caused by ipidacrine.

Cerebrolysin potentiates the effect of ipidacrine.

Alcohol increases the unwanted side effects of ipidacrine.

Ipidacrine can be used in combination with nootropic drugs.

Pregnancy and Lactation

Ipidacrine enhances the tone of the uterus and can cause premature labor, therefore it is contraindicated during pregnancy. The use of ipidacrine during breastfeeding is contraindicated.

Special instructions

Influence on ability to drive vehicles and work with mechanisms

Ipidacrine may have a sedative effect, so patients exposed to this effect when using the drug, should be careful when driving and working with mechanisms

Precautions for use

There are no systematic data on the use of children.

At the time of treatment should be excluded alcohol, which increases the side effects of ipidacrine.

Ipidacrine can aggravate the course of epilepsy, as well as increase the negative effect of alcohol on the body.

In patients with depression, ipidacrine may increase the symptoms of depression.

In connection with the possible risk of bradycardia when using ipidacrine, cardiac activity should be monitored.


Symptoms: severe overdose may develop a cholinergic crisis (loss of appetite, bronchospasm, lacrimation, sweating, constriction of the pupils, nystagmus, increased peristalsis of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, withdrawn, symptoms, and vascular disease hypotension, anxiety, anxiety, agitation, fear, ataxia, convulsions, coma, speech disorder, drowsiness, general weakness).

Treatment: carry out symptomatic therapy, apply m-cholinolytic substances (including atropine, cyclodol, metacin).

  • Brand name: Ipigrix
  • Active ingredient: Ipidacrine

Studies and clinical trials of Ipidacrine (Click to expand)

Customers who bought this product also bought:

8 other products in the same category: